Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

363
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
363
Pharmacovigilance01:19

Pharmacovigilance

963
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
963
Correlation of Experimental Data01:23

Correlation of Experimental Data

266
Dimensional analysis simplifies complex physical problems and guides experimental investigations, but it does not provide complete solutions. It identifies the dimensionless groups that influence a phenomenon, but experimental data is needed to establish the specific relationships and validate theoretical predictions.
For example, a spherical particle moving through a viscous fluid experiences drag. Dimensional analysis shows that the drag force depends on the particle's diameter, velocity,...
266
Longitudinal Research02:20

Longitudinal Research

12.1K
Sometimes we want to see how people change over time, as in studies of human development and lifespan. When we test the same group of individuals repeatedly over an extended period of time, we are conducting longitudinal research. Longitudinal research is a research design in which data-gathering is administered repeatedly over an extended period of time. For example, we may survey a group of individuals about their dietary habits at age 20, retest them a decade later at age 30, and then again...
12.1K
Pulse Oximetry01:24

Pulse Oximetry

393
Pulse oximetry, or SpO2, is a non-invasive method for continuously monitoring arterial oxygen saturation (SaO2). This procedure involves attaching a probe or sensor to the patient's fingertip, forehead, earlobe, or nose bridge. The sensor works by detecting changes in oxygen saturation levels through light signals generated by the oximeter and reflected by the pulsing blood under the probe.
Purpose
Average SpO2 values are greater than 95%. If the readings fall below 90%, it indicates that...
393
Longitudinal Studies01:26

Longitudinal Studies

215
Longitudinal studies are also widely used in other medical and social science fields. For instance, in cardiovascular research, they can monitor patients' health over decades to identify risk factors for heart disease, such as high cholesterol or smoking, and evaluate the long-term effectiveness of preventive measures. Similarly, in mental health studies, researchers might follow individuals from adolescence into adulthood to understand the development and progression of conditions like...
215

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Integrating social health assessments into routine clinical care.

The American journal of nursing·2026
Same author

Discharge bundles reduce length of stay.

The American journal of nursing·2026
Same author

ICU survivors experience multiple symptoms after discharge.

The American journal of nursing·2026
Same author

Web-based support intervention is beneficial for caregivers of patients with cancer.

The American journal of nursing·2026
Same author

Birth: From obscurity to hot topic.

Anatomical record (Hoboken, N.J. : 2007)·2026
Same author

Suboptimal engagement with home blood pressure monitoring.

The American journal of nursing·2026

Related Experiment Video

Updated: Aug 28, 2025

Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
09:38

Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease

Published on: November 14, 2017

15.0K

New Data on Paxlovid Reported.

Karen Rosenberg

    The American Journal of Nursing
    |September 22, 2022
    PubMed
    Summary

    This study found that Paxlovid did not meet its primary goal for standard-risk COVID-19 patients. However, a small benefit in reducing hospitalizations and death was observed in a specific subgroup with risk factors.

    Area of Science:

    • Virology
    • Clinical Medicine
    • Pharmaceuticals

    Background:

    • The COVID-19 pandemic necessitated the development of effective antiviral treatments.
    • Paxlovid emerged as a potential oral antiviral therapy for managing SARS-CoV-2 infections.
    • Understanding its efficacy in diverse patient populations is crucial for public health strategies.

    Purpose of the Study:

    • To evaluate the efficacy of Paxlovid in patients at standard risk for severe COVID-19.
    • To assess the primary endpoint of self-reported sustained symptom alleviation.
    • To investigate potential benefits in subgroups with risk factors for severe disease.

    Main Methods:

    • A phase 2/phase 3 clinical trial was conducted.
    • Participants included patients at standard risk for severe COVID-19.

    More Related Videos

    Examining BCL-2 Family Function with Large Unilamellar Vesicles
    08:35

    Examining BCL-2 Family Function with Large Unilamellar Vesicles

    Published on: October 5, 2012

    8.0K
    In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila
    06:41

    In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila

    Published on: August 20, 2019

    13.8K

    Related Experiment Videos

    Last Updated: Aug 28, 2025

    Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
    09:38

    Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease

    Published on: November 14, 2017

    15.0K
    Examining BCL-2 Family Function with Large Unilamellar Vesicles
    08:35

    Examining BCL-2 Family Function with Large Unilamellar Vesicles

    Published on: October 5, 2012

    8.0K
    In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila
    06:41

    In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila

    Published on: August 20, 2019

    13.8K
  • The primary endpoint focused on sustained symptom relief over four consecutive days.

    • Main Results:

    • The primary endpoint of sustained symptom alleviation was not met in the overall standard-risk group.
    • A nonsignificant risk reduction for hospitalizations and death was observed in a subgroup of patients with at least one risk factor for severe COVID-19.

    Conclusions:

    • Paxlovid did not demonstrate efficacy in meeting the primary endpoint for symptom alleviation in standard-risk COVID-19 patients.
    • Further research may be needed to clarify the role of Paxlovid in specific patient subgroups with risk factors.
    • The findings highlight the importance of targeted treatment strategies based on individual patient risk profiles.